Health Experts Advocate for Name Change in Women's Condition PCOS

Polycystic ovary syndrome (PCOS) has been one of the most prevalent hormonal disorders affecting women of reproductive age for many years. Recent discussions among healthcare professionals suggest a shift from the term 'polycystic ovary syndrome' to 'polyendocrine metabolic ovarian syndrome' (PMOS). This change aims to better encapsulate the multifaceted hormonal and metabolic effects the condition has on the body.

Recognised first in the 1930s, PMOS is associated with symptoms like irregular menstrual cycles, infertility, excess body or facial hair, and enlarged ovaries containing multiple small follicles. However, contemporary research has revealed that the condition is significantly more intricate than previously understood. The term PMOS highlights the combination of genetic and hormonal factors affecting insulin and metabolism, along with reproductive hormones.

Dr. Kevin Hoag, a gynecologic surgeon at Saint Peter’s University Hospital, emphasised the challenges posed by the existing terminology. He stated, 'Many women diagnosed with PCOS don’t actually have ovarian cysts. Relying on the name alone can sometimes delay diagnosis by two to three years while women search for answers to their symptoms.' This name change is intended to aid both patients and healthcare providers in recognising the condition promptly.

The long-term implications of PMOS on metabolic health are significant, with around 50% of women with the condition likely to develop Type 2 diabetes during their lifetime. Dr. Hoag remarked, 'By recognising PMOS early, we can screen for diabetes and other metabolic conditions, begin treatment sooner, and help reduce the risk of serious complications.'

Diagnosis of PMOS is not straightforward, as no single test can confirm the condition. Medical professionals assess symptoms, patient history, hormone levels, and utilise imaging studies while excluding other potential causes. Tests such as the measurement of anti-Mullerian hormone (AMH) assist in evaluation. Early diagnosis can lead to better monitoring for diabetes and cardiovascular issues, as well as facilitate timely treatment.

Delay in treatment can lead to severe complications, such as an increased risk of endometrial cancer due to extended menstrual cycle gaps. Additionally, symptoms arising from elevated androgen levels may become difficult to reverse if left unaddressed.

While there is currently no cure for PMOS, a variety of treatment options are available, tailored to each woman's health goals. Treatment could include lifestyle changes, medication, or other interventions to manage symptoms effectively.

Notably, GLP-1 receptor agonists have emerged as a promising treatment for PMOS, originally developed for Type 2 diabetes and obesity. Many women with PMOS experience insulin resistance, and these medications can help enhance insulin sensitivity, promote weight loss, and improve overall metabolic health. For some patients, even moderate weight loss can restore regular ovulation and menstrual cycles, significantly reducing the risk of diabetes.

It is important for patients to consult healthcare professionals to determine the most suitable treatment options based on individual health status and objectives. With ongoing awareness and education around PMOS, women and healthcare providers can work collaboratively towards better understanding and management of the condition.